Genetics of Alzheimer's disease: recent advances

Alzheimer's disease is a progressive neurodegenerative disorder with high prevalence in old age. It is the most common cause of dementia, with a risk reaching 50% after the age of 85 years, and with the increasing age of the population it is one of the biggest healthcare challenges of the 21st century. Genetic variation is an important contributor to the risk for this disease, underlying an estimated heritability of about 70%. Alzheimer's genetics research in the 1990s was successful in identifying three genes accounting for most cases of early-onset disease with autosomal dominant inheritance, and one gene involved in the more common late-onset disease, which shows complex inheritance patterns. Despite the presence of significant remaining genetic contribution to the risk, the identification of genes since then has been elusive, reminiscent of most other complex disorders. In the past decade there have been significant efforts towards a systematic evaluation of the multiple genetic association studies for Alzheimer's disease, while the first genome-wide association studies are now being reported with promising results. As sample sizes grow through new collections and collaborative efforts, and as new technologies make it possible to test alternative hypotheses, it is expected that new genes involved in the disease will soon be identified and confirmed. The gene discoveries of the 1990s have taught us a lot about Alzheimer's disease pathogenesis, providing many therapeutic targets that are currently at various stages of testing for future clinical use. As new genes become known and the biological pathways leading to disease are further explored, the possibility of prevention and successful personalized treatment is becoming tangible, providing hope for the millions of patients with Alzheimer's disease and their caregivers.

[1]  A. Alzheimer Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[2]  Johannes Schottky Über präsenile Verblödungen , 1932 .

[3]  R. Waggoner,et al.  FAMILIAL ORGANIC PSYCHOSIS (ALZHEIMER'S TYPE) , 1934 .

[4]  C. Worster-Drought,et al.  FAMILIAL PRESENILE DEMENTIA , 1939, Journal of neurology and psychiatry.

[5]  O. Hill A Twin Study , 1968, British Journal of Psychiatry.

[6]  J. Haines The genetics of Alzheimer disease--a teasing problem. , 1991, American journal of human genetics.

[7]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[8]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[10]  E M Wijsman,et al.  A familial Alzheimer's disease locus on chromosome 1 , 1995, Science.

[11]  J. Haines,et al.  Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. , 1997, JAMA.

[12]  K. Engedal,et al.  The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. , 1997, Archives of general psychiatry.

[13]  K Johansson,et al.  Heritability for Alzheimer's disease: the study of dementia in Swedish twins. , 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

[14]  E. Kojro,et al.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Sirotkin,et al.  dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.

[16]  S. P. Fodor,et al.  Blocks of Limited Haplotype Diversity Revealed by High-Resolution Scanning of Human Chromosome 21 , 2001, Science.

[17]  A. Myers,et al.  The genetics of late-onset Alzheimer's disease , 2001, Current opinion in neurology.

[18]  J. H. Lee,et al.  Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics. , 2002, American journal of human genetics.

[19]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[20]  M. Owen,et al.  Full genome screen for Alzheimer disease: stage II analysis. , 2002, American journal of medical genetics.

[21]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[22]  V. Crentsil The pharmacogenomics of Alzheimer’s disease , 2004, Ageing Research Reviews.

[23]  R. Bullock Future directions in the treatment of Alzheimer’s disease , 2004, Expert opinion on investigational drugs.

[24]  F. Fahrenholz,et al.  Genomic structure and functional characterization of the human ADAM10 promoter , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  P. Doraiswamy,et al.  Statins and Cognition: What Can We Learn from Existing Randomized Trials? , 2005, CNS Spectrums.

[26]  R. Tanzi,et al.  Genetic heterogeneity of gene defects responsible for familial Alzheimer disease , 2005, Genetica.

[27]  D. Campion,et al.  Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: an update , 2005, Journal of Medical Genetics.

[28]  M. Rowan,et al.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.

[29]  S. Bassett,et al.  Testing groups of genomic locations for enrichment in disease loci using linkage scan data: A method for hypothesis testing , 2006, Human Genomics.

[30]  F. Fahrenholz,et al.  α-Secretase Activation – An Approach to Alzheimer’s Disease Therapy , 2006, Neurodegenerative Diseases.

[31]  K. Rockwood,et al.  Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[32]  J. Gilbert,et al.  Covariate analysis of late-onset Alzheimer disease refines the chromosome 12 locus , 2006, Molecular Psychiatry.

[33]  F. Fahrenholz,et al.  Alpha-secretase activation--an approach to Alzheimer's disease therapy. , 2006, Neuro-degenerative diseases.

[34]  S. Resnick,et al.  0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(5):1802–1810 Printed in U.S.A. Copyright © 2006 by The Endocrine Society doi: 10.1210/jc.2005-2097 Effects of Combination Estrogen Plus Progestin Hormone Treatment on Cognition an , 2022 .

[35]  P. Jeffrey,et al.  Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .

[36]  Winnie S. Liang,et al.  GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. , 2007, Neuron.

[37]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[38]  P. Zandi,et al.  NSAIDs for the chemoprevention of Alzheimer's disease. , 2007, Sub-cellular biochemistry.

[39]  Winnie S. Liang,et al.  GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers , 2007, Neuron.

[40]  P. Jeffrey,et al.  Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. , 2007, Journal of neurochemistry.

[41]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[42]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[43]  D. Lahiri Apolipoprotein E as a target for developing new therapeutics for Alzheimer’s disease based on studies from protein, RNA, and regulatory region of the gene , 2007, Journal of Molecular Neuroscience.

[44]  M. Gill,et al.  Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. , 2007, Human molecular genetics.

[45]  Rebecca F. Halperin,et al.  A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. , 2007, The Journal of clinical psychiatry.

[46]  R. Tanzi,et al.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.

[47]  Ramón Cacabelos,et al.  Pharmacogenomics in Alzheimer's disease. , 2000, Methods in molecular biology.

[48]  Arun K. Ghosh,et al.  Memapsin 2 (beta-secretase) inhibitors: drug development. , 2008, Current Alzheimer research.

[49]  K. Ritchie,et al.  Hormonal treatment, mild cognitive impairment and Alzheimer's disease , 2008, International Psychogeriatrics.

[50]  Sven Cichon,et al.  A genome-wide association study for late-onset Alzheimer's disease using DNA pooling , 2008, BMC Medical Genomics.

[51]  K. Lapane,et al.  Dementia of the Alzheimer type. , 2008, Epidemiologic reviews.

[52]  J. Poirier Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer’s disease , 2008, Alzheimer's & Dementia.

[53]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[54]  M. Block,et al.  Retinoic Acid Attenuates β-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model , 2008, The Journal of Neuroscience.

[55]  M. Daly,et al.  Genetic Mapping in Human Disease , 2008, Science.

[56]  F. Pasquier,et al.  Association study of the GAB2 gene with the risk of developing Alzheimer's disease , 2008, Neurobiology of Disease.

[57]  Eden R Martin,et al.  Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. , 2009, American journal of human genetics.

[58]  Ronald C. Petersen,et al.  Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Alzheimer's & Dementia.

[59]  Takashi Asada,et al.  GAB2 is not associated with late-onset Alzheimer's disease in Japanese , 2009, European Journal of Human Genetics.

[60]  M. Arfan Ikram,et al.  The GAB2 Gene and the Risk of Alzheimer's Disease: Replication and Meta-Analysis , 2009, Biological Psychiatry.

[61]  Sebastiaan Engelborghs,et al.  Common variation in GRB‐associated Binding Protein 2 (GAB2) and increased risk for Alzheimer dementia , 2009, Human mutation.

[62]  M. Wolfe Inhibition and modulation of γ-secretase for Alzheimer’s disease , 2008, Neurotherapeutics.